articleTop 1% cited

A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis

Lara D. Veeken · 2000 · Vol. 39(6) · pp. 655–665

Paul Emery✉(University of Leeds)FC BreedveldE.‐M. LemmelJ. P. KaltwasserP. T. DawesB GömörFilip Van den BoschDan NordströmOlav BjørneboeRasmus Holmboe DahlKim Hørslev‐PetersenArturo Rodríguez de la SernaMiriam MolloyMohammed TiklyChristine OedRonald RosenburgIris Loew-Friedrich

View via DOI Publisher page

Abstract

Both leflunomide and methotrexate are efficacious for prolonged treatment of RA. At the doses used, some clinical benefit of methotrexate over leflunomide was observed in the first year of treatment. This benefit must be weighed against the potential toxicity of this drug when used without folate supplementation.

Rheumatoid Arthritis Research and Therapies Chronic Lymphocytic Leukemia Research Lymphoma Diagnosis and TreatmentLeflunomideMedicineMethotrexateRheumatoid arthritisErythrocyte sedimentation rateNauseaRashInternal medicineAdverse effectArthritis

MeSH terms

LeflunomideAdolescentAdultArthritis, RheumatoidDouble-Blind MethodDrug Therapy, CombinationFemaleHumansImmunosuppressive AgentsIsoxazolesMaleMethotrexateRadiographyTreatment OutcomeOutcome Assessment, Health Care

Citations

469

FWCI

26.49

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Guidelines for the management of rheumatoid arthritis: 2002 Update